ZVSAOTCPharmaceutical PreparationsFiscal year ends December 31
ZyVersa Therapeutics, Inc.
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on May 13, 2026
$0.05+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $388.60K
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Sep 30, 2025, from 13F filings
Held by institutions
0.0%
0M of 8M shares
Institutional holders
1
1 new, 6 sold out
Net institutional buying
-0M
In Q3 2025
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Armistice Capital, LLC | 285,037 | 9.99% | 13G (passive) | Mar 31, 2025 |
Top institutional holders
13F holdings as of Sep 30, 2025
| Holder | Shares | % of ZVSA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Guerra Advisors Inc | 7 | 0.00% | $1 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q3 2025 | 1 | 0M | 0.0% | 1 / 0 | 0 / 6 | 0M | 0M |
| Q2 2025 | 6 | 0M | 0.8% | 1 / 4 | 0 / 2 | 0M | 0M |
| Q1 2025 | 7 | 0M | 0.9% | 1 / 2 | 2 / 2 | 0M | 0M |
| Q4 2024 | 8 | 0M | 1.0% | 4 / 3 | 0 / 2 | 0M | 0M |
| Q3 2024 | 6 | 0M | 0.0% | 3 / 2 | 0 / 1 | 0M | 0M |
| Q2 2024 | 4 | 0M | 0.1% | 4 / 0 | 0 / 0 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Stephen C. Glover | Chief Executive Officer, Director | 578,198 | 7.14% | Jul 15, 2025 |
| Karen A. Cashmere | Chief Commercial Officer | – | – | Jul 16, 2025 |
| Pablo A. Guzman | Chief Medical Officer | 26,021 | 0.32% | Jul 15, 2025 |
| Peter Wolfe | Chief Financial Officer | 44,585 | 0.55% | Jul 15, 2025 |
| James Sapirstein | Director | – | – | Jul 15, 2025 |
| Gregory Gene Freitag | Director | – | – | Jul 15, 2025 |
| Min-Chul Park | Director | – | – | Jul 15, 2025 |
| Robert G. Finizio | Director | – | – | Jul 15, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Peter Wolfe Chief Financial Officer | Dec 16, 2022 | Award | +3,000 | $2.88 | $8.64K | 44,585 |
| INCON Co., Ltd. 10% owner | Dec 12, 2022 | Award | +1,497,199 | – | – | 1,497,199 |
| Daniel J. O'Connor Director, 10% owner | Dec 12, 2022 | Other | +1,377,598 | – | – | 1,377,598 |
| Nicholas A. LaBella Jr. Chief Scientific Officer | Dec 12, 2022 | Award | +18,094 | – | – | 18,094 |
| Stephen C. Glover Chief Executive Officer, Director | Dec 12, 2022 | Award | +43,847 | – | – | 43,847 |
| Stephen C. Glover Chief Executive Officer, Director | Dec 12, 2022 | Award | +448,909 | – | – | 448,909 |
| Stephen C. Glover Chief Executive Officer, Director | Dec 12, 2022 | Award | +85,442 | – | – | 85,442 |
| Stephen C. Glover Chief Executive Officer, Director | Dec 12, 2022 | Award | +49,636 | – | – | 49,636 |
| Peter Wolfe Chief Financial Officer | Dec 12, 2022 | Award | +41,585 | – | – | 41,585 |
| / Alliance Global Partners Corp. A.G.P. 10% owner | Mar 8, 2022 | Other | −3,427 | – | – | 446,843 |
| / Alliance Global Partners Corp. A.G.P. 10% owner | Feb 3, 2022 | Other | −49,730 | – | – | 450,270 |
| Daniel J. O'Connor Chief Executive Officer, Director | Jan 6, 2022 | Other | +42,005 | – | – | 42,005 |
| Health LLC Larkspur 10% owner | Jan 6, 2022 | Other | +236,273 | – | – | 236,273 |
| David S. Briones Chief Financial Officer, Director | Jan 6, 2022 | Other | +10,752 | – | – | 10,752 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.